<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01631474</url>
  </required_header>
  <id_info>
    <org_study_id>171-7151-201</org_study_id>
    <nct_id>NCT01631474</nct_id>
  </id_info>
  <brief_title>A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intrepid Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intrepid Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CB-03-01 is being developed for the topical treatment of acne vulgaris, an androgen-dependent
      skin disorder. The purpose of this study is to compare the safety and efficacy of multiple
      concentrations of CB-03-01 to vehicle in the treatment of acne vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator's Global Assessment (IGA) &quot;Success&quot; - Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Proportion of subjects achieving success in each treatment group at Week 12 using the dichotomized IGA with success defined as a score of &quot;clear&quot; or &quot;almost clear&quot; (IGA Score of 0 or 1) and a two or more grade improvement from Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory and Non-Inflammatory Lesion Counts - Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Absolute change from Baseline in inflammatory and non-inflammatory lesion counts in each treatment group at Week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory and Non-Inflammatory Lesion Counts - Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Absolute change from Baseline in inflammatory and non-inflammatory lesion counts in each treatment group at Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Lesion Counts - Weeks 8 and 12</measure>
    <time_frame>Baseline, Week 8 and Week 12</time_frame>
    <description>Percent change from Baseline in lesion counts in each treatment group at Weeks 8 and 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGA &quot;Success&quot; - Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Proportion of subjects achieving success per the IGA in each treatment group at Week 8 (&quot;success&quot; as defined in the primary endpoints section).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGA &quot;Clear&quot; or &quot;Almost Clear&quot; - Weeks 4, 8 and 12</measure>
    <time_frame>Baseline, Week 4, Week 8 and Week 12</time_frame>
    <description>Proportion of subjects who are &quot;clear&quot; or &quot;almost clear&quot; (IGA Grade 0 or 1) in each treatment group at Weeks 4, 8 and 12.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">363</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Low-dose active, BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose of CB-03-01, applied twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium-dose active, BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>medium dose of CB-03-01, applied twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose active, QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose of CB-03-01, applied once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose active, BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose of CB-03-01, applied twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle, QD or BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vehicle cream, applied once or twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-03-01</intervention_name>
    <description>Topical cream, applied once a day</description>
    <arm_group_label>High-dose active, QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Topical cream, applied once or twice a day</description>
    <arm_group_label>Vehicle, QD or BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-03-01</intervention_name>
    <description>Topical cream, applied twice a day</description>
    <arm_group_label>Low-dose active, BID</arm_group_label>
    <arm_group_label>Medium-dose active, BID</arm_group_label>
    <arm_group_label>High-dose active, BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is male or non-pregnant female. Females must be post-menopausal, surgically
             sterile or using highly effective birth control methods.

          -  Subject has provided written and verbal informed consent/assent.

          -  Subject has facial acne vulgaris (including the nose).

          -  Subject is willing to comply with study instructions and return to the clinic for
             required visits.

          -  Subject has used the same type and brand of make-up, other facial products (including
             cleanser) and hair products (e.g., shampoo, gel, hair spray, mousse, etc.) for at
             least one month prior to the study start and agrees to continue his/her other general
             skin and hair care products and regimen for the entire study.

        Exclusion Criteria:

          -  Subject is pregnant, lactating, or is planning to become pregnant during the study.

          -  Subject is currently enrolled in an investigational drug or device study.

          -  Subject has received an investigational drug or been treated with an investigational
             device within 30 days prior to the study start.

          -  Subject has the need or plans to be exposed to artificial tanning devices or excessive
             sunlight during the trial

          -  Subject has used any of the following topical anti-acne preparations or procedures on
             the face:

               -  Topical anti-acne treatments including but not limited to over-the-counter acne
                  cleaners or treatments, benzoyl peroxide, antibiotics, azelaic acid, sulfa based
                  products, corticosteroids and salicylic acid within two weeks of the initiation
                  of treatment.

               -  Retinoids, including tazarotene, adapalene, tretinoin, within four weeks of the
                  initiation of treatment.

               -  Light treatments, microdermabrasion or chemical peels within eight weeks of the
                  initiation of treatment.

          -  Subject has used the following systemic anti-acne medications:

               -  Corticosteroids (including intramuscular and intralesional injections) within
                  four weeks of the initiation of treatment. Inhaled, intranasal or ocular
                  corticosteroids are allowed if use is stable (stable use is defined as dose and
                  frequency unchanged for at least four weeks prior to the initiation of
                  treatment).

               -  Antibiotics within four weeks of the initiation of treatment with the exception
                  of five days or less of antibiotic therapy during this period, but with no
                  antibiotics use permitted within one week prior to the initiation of treatment.

               -  Spironolactone within eight weeks of the initiation of treatment with the
                  exception of five days or less of spironolactone therapy during this period, but
                  with no spironolactone use permitted within one week prior to the initiation of
                  treatment.

               -  Retinoid therapy within six months of the initiation of treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Syd Dromgoole, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therapeutics Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Trials</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Clinical Research - US, LLC</name>
      <address>
        <city>Sanford</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gwinnett Clinical Research Center, Inc.</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altman Dermatology Associates</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Clinical Trials Center</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marina I. Peredo, M.D., PC</name>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center - Dept. of Dermatology</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Partners, LLC</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J &amp; S Studies</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Houston Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2012</study_first_submitted>
  <study_first_submitted_qc>June 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2012</study_first_posted>
  <disposition_first_submitted>March 27, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 27, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 16, 2015</disposition_first_posted>
  <last_update_submitted>March 27, 2015</last_update_submitted>
  <last_update_submitted_qc>March 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intrepid</keyword>
  <keyword>acne</keyword>
  <keyword>antiandrogen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

